Cardiology
GLP-1 receptor agonists in cardiometabolic and obesity research, including cardiovascular outcome trials and mechanistic studies.
Synthesized from 12 evidence-backed clinical questions linked to this topic — 4 supporting the intervention, 2 against the intervention.
Does glp-1 receptor agonist vs placebo improve outcomes in orthopaedic surgery?
Low Certainty− Favors harmglp-1 receptor agonist vs placebo
2 studies (392,065 patients) provide low-certainty evidence against benefit of glp-1 receptor agonist for the outcome in orthopaedic surgery.
Does glp-1 receptor agonists vs dpp-4 inhibitors improve outcomes in Diabetes Mellitus, Type 2?
Low Certainty+ Favors benefitglp-1 receptor agonists vs dpp-4 inhibitors
4 studies (276,715 patients) provide low-certainty evidence for benefit of glp-1 receptor agonists for the outcome in Diabetes Mellitus, Type 2.
Does glp-1 ra vs placebo improve All-Cause Mortality in lumbar fusion?
Low Certainty+ Favors benefitglp-1 ra vs placebo · All-Cause Mortality
2 studies (17,102 patients) provide low-certainty evidence for benefit of glp-1 ra for All-Cause Mortality in lumbar fusion.
Does glp-1 receptor agonist vs sglt2 inhibitor improve outcomes in Diabetes Mellitus, Type 2?
Low Certainty+ Favors benefitglp-1 receptor agonist vs sglt2 inhibitor
5 studies (1,974 patients) provide low-certainty evidence for benefit of glp-1 receptor agonist for the outcome in Diabetes Mellitus, Type 2.
Does glp-1 receptor agonist vs placebo improve outcomes in Diabetes Mellitus, Type 2?
Low Certainty− Favors harmglp-1 receptor agonist vs placebo
5 studies (0 patients) provide low-certainty evidence against benefit of glp-1 receptor agonist for the outcome in Diabetes Mellitus, Type 2.
Does glp-1 receptor agonists vs placebo improve outcomes in Sleep Apnea, Obstructive?
Low Certainty+ Favors benefitglp-1 receptor agonists vs placebo
3 studies (0 patients) provide low-certainty evidence for benefit of glp-1 receptor agonists for the outcome in Sleep Apnea, Obstructive.
No claims extracted for this topic
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Postprandial renal haemodynamic effect of lixisenatide vs once‐daily insulin‐glulisine in patients with type 2 diabetes on insulin‐glargine: An 8‐week, randomised, open‐label trial
Diabetes Obesity and Metabolism — Tonneijck L — Apr 2017
Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure
Biomolecules — Crispino S — Nov 2025
Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure
Diabetes and Vascular Disease Research — Mortada I — Jul 2026
Long-Term Health Care Utilization Costs of GLP-1RA Use vs Bariatric Metabolic Surgery
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
GLP-1 receptor agonists (also known as GLP-1, GLP-1 RA, incretin). GLP-1 receptor agonists in cardiometabolic and obesity research, including cardiovascular outcome trials and mechanistic studies.
Synapse tracks 1 specific clinical question in GLP-1 receptor agonists, synthesizing the evidence for it independently: "Does glp-1 ra vs placebo improve All-Cause Mortality in lumbar fusion?".
As of 2026-08-14, the scientific consensus on GLP-1 receptor agonists is unknown. No claims extracted for this topic
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/peptide-glp-1.
Deterministic synthesis from Synapse's enriched corpus — 81 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every GLP-1 receptor agonists paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search GLP-1 receptor agonists papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
JAMA Network Open — Sagy Y — Jul 2026
